Experimental evaluation on a curated glioma CD34 dataset demonstrates that PGE-Net achieves notable improvements over ResNet18 baselines, with Precision, Recall, and F1-score increased by 9.17%, 9.35%, and 12.35%, respectively. The gene discussed is CD34; the disease is glioma.